- Home
- TPCS vs NRSN Comparison
TPCS vs NRSN Comparison
Compare TPCS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- NRSN
- Stock Information
- Founded
- TPCS 1956
- NRSN 2017
- Country
- TPCS United States
- NRSN Israel
- Employees
- TPCS N/A
- NRSN N/A
- Industry
- TPCS Metal Fabrications
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TPCS Industrials
- NRSN Health Care
- Exchange
- TPCS Nasdaq
- NRSN Nasdaq
- Market Cap
- TPCS 42.6M
- NRSN 45.3M
- IPO Year
- TPCS N/A
- NRSN 2021
- Fundamental
- Price
- TPCS $3.74
- NRSN $2.06
- Analyst Decision
- TPCS
- NRSN Buy
- Analyst Count
- TPCS 0
- NRSN 2
- Target Price
- TPCS N/A
- NRSN $14.00
- AVG Volume (30 Days)
- TPCS 29.5K
- NRSN 321.5K
- Earning Date
- TPCS 04-08-2025
- NRSN 07-22-2025
- Dividend Yield
- TPCS N/A
- NRSN N/A
- EPS Growth
- TPCS N/A
- NRSN N/A
- EPS
- TPCS N/A
- NRSN N/A
- Revenue
- TPCS $33,154,058.00
- NRSN N/A
- Revenue This Year
- TPCS N/A
- NRSN N/A
- Revenue Next Year
- TPCS N/A
- NRSN N/A
- P/E Ratio
- TPCS N/A
- NRSN N/A
- Revenue Growth
- TPCS 8.71
- NRSN N/A
- 52 Week Low
- TPCS $2.05
- NRSN $0.51
- 52 Week High
- TPCS $4.42
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- TPCS 54.79
- NRSN 57.09
- Support Level
- TPCS $3.45
- NRSN $1.84
- Resistance Level
- TPCS $3.85
- NRSN $2.19
- Average True Range (ATR)
- TPCS 0.23
- NRSN 0.19
- MACD
- TPCS 0.00
- NRSN -0.03
- Stochastic Oscillator
- TPCS 62.32
- NRSN 45.62
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.